Peregrine Capital Management’s Insmed INSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-88,695
Closed -$8.93M – 346
2025
Q2
$8.93M Sell
88,695
-92,298
-51% -$7.06M 0.27% 101
2025
Q1
$13.8M Sell
180,993
-12,486
-6% -$955K 0.46% 37
2024
Q4
$13.4M Buy
193,479
+20,642
+12% +$1.49M 0.4% 48
2024
Q3
$12.6M Sell
172,837
-7,095
-4% -$524K 0.38% 54
2024
Q2
$12.1M Sell
179,932
-110,242
-38% -$4.28M 0.35% 58
2024
Q1
$7.87M Buy
290,174
+86
+0% +$2.41K 0.23% 135
2023
Q4
$8.99M Sell
290,088
-50,037
-15% -$1.3M 0.27% 102
2023
Q3
$8.59M Sell
340,125
-21,396
-6% -$489K 0.26% 146
2023
Q2
$7.63M Sell
361,521
-126
-0% -$2.39K 0.21% 201
2023
Q1
$6.17M Buy
361,647
+10,678
+3% +$207K 0.18% 230
2022
Q4
$7.01M Sell
350,969
-10,634
-3% -$206K 0.22% 208
2022
Q3
$7.79M Buy
361,603
+31,915
+10% +$765K 0.25% 185
2022
Q2
$6.5M Sell
329,688
-274
-0.1% -$5.74K 0.2% 227
2022
Q1
$7.75M Sell
329,962
-23,665
-7% -$550K 0.18% 220
2021
Q4
$9.63M Buy
353,627
+9,978
+3% +$285K 0.19% 207
2021
Q3
$9.46M Buy
+343,649
New +$9.02M 0.2% 217

Other funds holding INSM

Peregrine Capital Management's INSM Position: Q3 2025 in Review

Peregrine Capital Management sold out of Insmed (INSM) in Q3 2025, closing a stake of 88,695 shares — an estimated $8.93M sold.

Peregrine Capital Management first reported a position in INSM in Q3 2021 and held it in 16 quarters. The position peaked at $13.8M in Q1 2025. 566 funds tracked by Wall St. Rank hold INSM as of Q3 2025.

  • Peregrine Capital Management reported no remaining Insmed position as of Q3 2025 after selling out during the quarter.
  • Peregrine Capital Management sold 88,695 Insmed shares in Q3 2025, an estimated $8.93M.
  • Peregrine Capital Management first reported a position in Insmed in Q3 2021 and held it in 16 quarters.
  • Peregrine Capital Management's Insmed position peaked at $13.8M in Q1 2025.
  • 566 funds tracked by Wall St. Rank held Insmed as of Q3 2025.

Based on Peregrine Capital Management's 13F filing for Q3 2025, filed 23 Oct 2025.